Development of human-like scFv-Fc antibodies neutralizing botulinum toxin serotype B

mAbs

Volumn 7, Issue 6, 2015, Pages 1161-1177

  Rasetti Escargueil, Christine ^a   Avril, Arnaud ^b   Chahboun, Siham ^b   Tierney, Rob ^a   Bak, Nicola ^a   Miethe, Sebastian ^c   Mazuet, Christelle ^d   Popoff, Michel R ^d   Thullier, Philippe ^b   Hust, Michael ^c   Pelat, Thibaut ^b,e   Sesardic, Dorothea ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^c TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^d INSTITUT PASTEUR   (France)

^e BIOTEM   (France)

Author keywords

BoNT B; Botulinum neurotoxins; Ex vivo mouse phrenic nerve hemidiaphragm; In vitro endopeptidase; Mouse paralysis; Neutralization assays; ScFv Fc; Synergistic protection macaque; VAMP2

Indexed keywords

BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; BOTULINUM TOXIN A; PEPTIDE LIBRARY;

ANTIBODY PRODUCTION; ARTICLE; BACTERIAL COLONIZATION; BINDING AFFINITY; BOTULISM; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; LD50; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CLOSTRIDIUM; CROSS REACTION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MONKEY DISEASES; PARALYSIS; PEPTIDE LIBRARY; PHRENIC NERVE; PROCEDURES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BOTULINUM TOXINS, TYPE A; BOTULISM; CLOSTRIDIUM; CROSS REACTIONS; HUMANS; IMMUNIZATION; MACACA FASCICULARIS; MICE; MONKEY DISEASES; PARALYSIS; PEPTIDE LIBRARY; PHRENIC NERVE; SINGLE-CHAIN ANTIBODIES;

EID: 84954219468     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1082016     Document Type: Article

References (68)

1. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999; 291:1091-104; PMID:10518945; http://dx. doi. org/10. 1006/jmbi. 1999. 2945
2. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralisation. Infect Immun 2005; 73:5450-7; PMID:16113261; http://dx. doi. org/10. 1128/ IAI. 73. 9. 5450-5457. 2005
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285: 1059-70; PMID:11209178; http:// dx. doi. org/10. 1001/jama. 285. 8. 1059
4. Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, Langford MJ. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 1999; 19 Suppl 1:S35-8; PMID:10594898; http://dx. doi. org/ 10. 1002/(SICI)1099-1263(199912)19:1+%3cS35::AI D-JAT612%3e3. 0. CO;2-9
5. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982; 46:86-94; PMID:6806598
6. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3:333-5; PMID:3211180; http://dx. doi. org/10. 1002/mds. 870030409
7. Taysse L, Daulon S, Calvet J, Delamanche S, Hilaire D, Bellier B, Breton P. Induction of acute lung injury after intranasal administration of toxin botulinum a complex. Toxicol Pathol 2005; 33:336-42; PMID:15814363; http://dx. doi. org/10. 1080/ 01926230590922884
8. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A 2005; 102:9984-9; PMID:15985558; http://dx. doi. org/10. 1073/pnas. 0408526102
9. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56:80-99; PMID:1579114
10. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007; 189:818-32; PMID:17114256; http://dx. doi. org/10. 1128/JB. 01180-06
11. Kalb SR, Baudys J, Rees JC, Smith TJ, Smith LA, Helma CH, Hill K, Kull S, Kirchner S, Dorner MB, et al. De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal Bioanal Chem 2012; 403:215-26; PMID:22395449; http://dx. doi. org/10. 1007/s00216-012-5767-3
12. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, et al. Analysis of the neurotoxin complex genes in clostridium botulinum A1-A4 and B1 strains: BoNT/ A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One 2007; 2:e1271; PMID:18060065; http://dx. doi. org/10. 1371/journal. pone. 0001271
13. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986; 103:535-44; PMID:3015983; http://dx. doi. org/ 10. 1083/jcb. 103. 2. 535
14. Rossetto O, Montecucco, C. Presynaptic neurotoxins with enzymatic activities. Handb Exp Pharmacol 2008; 184:129-70; PMID:18064414; http://dx. doi. org/ 10. 1007/978-3-540-74805-2_6
15. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-5; PMID:1331807; http://dx. doi. org/10. 1038/359832a0
16. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80:717-66; PMID:10747206
17. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000; 7:389-94; PMID:10942658; http://dx. doi. org/10. 1054/ jocn. 2000. 0684
18. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 2013; 84:1014-9; PMID:23687362; http://dx. doi. org/10. 1136/jnnp-2012-303608
19. Lim ECH, Seet RCS. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010; 6:624-36; PMID:21045798; http://dx. doi. org/10. 1038/ nrneurol. 2010. 149
20. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399-411; PMID:9244332; http://dx. doi. org/10. 1001/jama. 1997. 03550050061035
21. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006; 354:462-71; PMID:16452558; http://dx. doi. org/ 10. 1056/NEJMoa051926
22. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567-70; PMID:7191633; http://dx. doi. org/10. 1016/0002-9343(80)90469-6
23. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem 2011; 12:58; PMID:22085466; http://dx. doi. org/10. 1186/1471-2091-12-58
24. Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, Simpson LL, Dessain SK. Hybridoma populations enriched for affinity-matured human IgGs yield highaffinity antibodies specific for botulinum neurotoxins. J Immunol Methods 2008; 333:156-66; PMID:18313069; http://dx. doi. org/10. 1016/j. jim. 2008. 01. 015
25. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 2002; 20:1640-8; PMID:11858873; http://dx. doi. org/10. 1016/S0264-410X(01)00482-0
26. Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RGA, Sesardic D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 2011; 57:1008-16; PMID:21513727; http://dx. doi. org/10. 1016/j. toxicon. 2011. 04. 003
27. Jones RG, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 2006; 48:246-54; PMID:16870221; http://dx. doi. org/10. 1016/j. toxicon. 2006. 05. 007
28. Zhou H, Zhou B, Pellett S, Johnson EA, Janda KD. Selection and characterization of a human monoclonal neutralizing antibody for clostridium botulinum neurotoxin serotype B. Bioorg Med Chem Lett 2009; 19:662-4; PMID:19112017; http://dx. doi. org/ 10. 1016/j. bmcl. 2008. 12. 055
29. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C. Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin, Protein Eng Des Sel 2011; 24:321-31; PMID:21149386; http://dx. doi. org/10. 1093/protein/ gzq111
30. Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2010; 2:528-38; PMID:20562531; http://dx. doi. org/10. 4161/mabs. 2. 5. 12545
31. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RGA, Sesardic D, Thullier P. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 2011; 11:113; PMID:22111995; http://dx. doi. org/10. 1186/1472-6750-11-113
32. Rasetti-Escargueil C, Jones RGA, Liu Y, Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009; 53:503-11; PMID:19673096; http://dx. doi. org/ 10. 1016/j. toxicon. 2009. 01. 019
33. Rasetti-Escargueil C, Machado CB, Preneta-Blanc R, Fleck RA, Sesardic D. Enhanced sensitivity to botulinum type A neurotoxin of human neuroblastoma SHSY5Y cells after differentiation into mature neuronal cells. Botulinum J 2011; 2:30-48; http://dx. doi. org/ 10. 1504/TBJ. 2011. 041814
34. Atassi MZ, Dolimbek BZ. Mapping of the antibodybinding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 2004; 23:39-52; PMID:15115181; http://dx. doi. org/10. 1023/B: JOPC. 0000016257. 91979. 06
35. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, Raffestin S, Popoff MR, Marvaud JC. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS letters 2004; 572:299-306; PMID:15304366; http://dx. doi. org/ 10. 1016/j. febslet. 2004. 06. 094
36. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DA, Root MJ, Kapadnis BP, Simpson LL, Dessain SK. Neutralization of Botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 2008; 3:e3023; PMID:18714390; http://dx. doi. org/10. 1371/journal. pone. 0003023
37. Avril A, Froude J, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol 2014; 11:20-7.
38. Thullier P, Huish O, Pelat T, Martin ACR. The humanness of macaque antibody sequences. J Mol Biol 2010; 396:1439-50; PMID:20043919; http://dx. doi. org/10. 1016/j. jmb. 2009. 12. 041
39. Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009; 9:60; PMID:19563687; http://dx. doi. org/10. 1186/1472-6750-9-60
40. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M-P, Bottex C, Thullier P. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49:3414-20; PMID:16048955; http://dx. doi. org/10. 1128/ AAC. 49. 8. 3414-3420. 2005
41. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall H-J et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PloS ONE 2012; 7:e37242; PMID:22666347; http://dx. doi. org/10. 1371/journal. pone. 0037242
42. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007; 25:107-16; PMID:17173035; http://dx. doi. org/ 10. 1038/nbt1269
43. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PloS ONE 2009; 4:e5355; PMID:19399171; http://dx. doi. org/ 10. 1371/journal. pone. 0005355
44. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS ONE 2010; 5:e12237; PMID:20808925; http://dx. doi. org/10. 1371/journal. pone. 0012237
45. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005;351:158-69; PMID:16002090; http://dx. doi. org/10. 1016/j. jmb. 2005. 06. 003
46. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50; PMID:12177434; http://dx. doi. org/10. 1073/ pnas. 172229899
47. Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB. Efficient serum clearance of Botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 2010; 78:756-763; PMID:19917718; http://dx. doi. org/10. 1128/ IAI. 01084-09
48. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS ONE 2012; 7: e29941; PMID:22238680; http://dx. doi. org/10. 1371/ journal. pone. 0029941
49. Diamant E, Lachmi B-E, Keren A, Barnea A, Marcuk H, Cohen S. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS ONE 2014; 9:87089; http://dx. doi. org/ 10. 1371/journal. pone. 0087089
50. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D. and Hust M. Development of neutralizing scFV-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs 2014; 6:446-459; PMID:24492304; http://dx. doi. org/10. 4161/ mabs. 27773
51. Abhinandan KR, Martin AC. Analyzing the "degree of humanness" of antibody sequences. J Mol Biol 2007; 369:852-62; PMID:17442342; http://dx. doi. org/ 10. 1016/j. jmb. 2007. 02. 100
52. Pelat T, Hust M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 2009; 9:1633-8; PMID:20105119; http://dx. doi. org/10. 2174/ 138955709791012283
53. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a nonhuman primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384:1400-7; PMID:18976662; http://dx. doi. org/10. 1016/j. jmb. 2008. 10. 033
54. Mazuet C, Dano J, Popoff MR, Creminon C, Volland H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS ONE 2010; 5:e12416; PMID:20865035; http://dx. doi. org/ 10. 1371/journal. pone. 0012416
55. Shone CC, Tranter HS. Growth of Clostridia and preparation of their neurotoxins. In Montecucco C (Ed.), Clostridial neurotoxins. Berlin: Springer-Verlag, 1995:143-160
56. Ferracci G, Marconi S, Mazuet C, Jover E, Blanchard MP, Seagar M, Popoff M, Lévêque C. A label-free biosensor assay for botulinum neurotoxin B in food and human serum. Anal Biochem 2011; 410:281-288; PMID:21134347; http://dx. doi. org/10. 1016/j. ab. 2010. 11. 045
57. Hust M, Dübel S. Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol 2005; (Clifton, N. J.), 295, 71-96. http:// www. ncbi. nlm. nih. gov/pubmed/15596889; PMID:15596889
58. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI, Hasenberg M, Frank R, Schirrmann T, Gunzer M, Hust M, Dübel S. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PloS ONE 2009; 4:e6625; PMID:19675673; http://dx. doi. org/10. 1371/journal. pone. 0006625
59. Frenzel A, Kügler J, Wilke S, Schirrmann T, Hust. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2014;1060:215-43; PMID:24037844; http://dx. doi. org/10. 1007/978-1-62703-586-6_12
60. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, Lefranc P, Dübel S, Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID:17517846; http://dx. doi. org/10. 1128/AAC. 01528-06
61. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013;13:52; http:// dx. doi. org/10. 1186/1472-6750-13-52
62. Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evenescent wave biosensors. Anal Biochem 1996; 240:262-272; PMID:8811920; http://dx. doi. org/10. 1006/abio. 1996. 0356
63. Alamyar E, Duroux P, Lefranc MP, Giudicelli V. IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol Biol 2012; 882:569-604; PMID:22665256; http://dx. doi. org/10. 1007/978-1-61779-842-9_32
64. Ehrenmann F, Lefranc MP. IMGT/DomainGapAlign: the IMGT® tool for the analysis of IG, TR, MH, IgSF, and MhSF domain amino acid polymorphism. Methods Mol Biol 2012; 882:605-33; PMID:22665257; http://dx. doi. org/10. 1007/978-1-61779-842-9_33
65. Lefranc MP, Ehrenmann F, Ginestoux C, Giudicelli V, Duroux P. Use of IMGT(®) databases and tools for antibody engineering and humanization. Methods Mol Biol 2012; 907:3-37; PMID:22907343; http://dx. doi. org/10. 1007/978-1-61779-974-7_1
66. Jones RGA, Ochiai M, Liu Y, Ekong T, Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods 2008; 329:92-101; PMID:17976638; http://dx. doi. org/10. 1016/j. jim. 2007. 09. 014
67. Sesardic D, McLellen K, Ekong TA, Das RG. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996; 78:283-8; PMID:8737961; http://dx. doi. org/10. 1111/j. 1600-0773. 1996. tb01376. x
68. Sesardic D, Jones RGA, Leung T, Alsop T, Tierney R. Detection of antibodies against botulinum toxins. Mov Disord 2004; 19:85-91; http://dx. doi. org/ 10. 1002/mds. 20021